TrialGynecologic oncology2010

Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.

Stephanie V Blank et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.